Candel Therapeutics (NASDAQ:CADL) Trading Down 4.6% on Disappointing Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) traded down 4.6% during trading on Friday after the company announced weaker than expected quarterly earnings. The stock traded as low as $11.04 and last traded at $11.2560. Approximately 300,318 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 1,519,494 shares. The stock had previously closed at $11.80.

The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.25).

Key Headlines Impacting Candel Therapeutics

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: Management highlighted “meaningful execution” toward a BLA submission expected in the fourth quarter, reinforcing the company’s near-term regulatory and development milestones. Candel is also targeting a potential first commercial product in 2027, which could support a significant change in its long-term revenue outlook. CADL rises as biotech eyes first commercial product in 2027
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $23 price target, implying substantial upside from recent trading levels. The continued bullish rating indicates the analyst sees value in Candel’s pipeline and upcoming regulatory milestones. HC Wainwright reaffirms Candel Therapeutics rating
• Neutral Sentiment: Candel reported second-quarter 2026 results and provided a corporate update. As a clinical-stage biotechnology company, its valuation remains driven primarily by development, regulatory and commercialization progress rather than current revenue. Candel Therapeutics reports second-quarter 2026 results
• Negative Sentiment: Candel reported a quarterly loss of $0.52 per share, significantly worse than the $0.27 analyst consensus. The earnings miss highlights continued cash-burn and execution risk ahead of a potential product launch.
• Negative Sentiment: HC Wainwright modestly reduced its FY2028 EPS forecast to $0.69 from $0.71 and its FY2029 estimate to $1.41 from $1.45. Although the analyst maintained a Buy rating and $23 target, the lower estimates temper some of the long-term optimism.

Analysts Set New Price Targets

CADL has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Stifel Nicolaus began coverage on Candel Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $22.00 target price on the stock. Cantor Fitzgerald initiated coverage on Candel Therapeutics in a research report on Monday, April 20th. They set an “overweight” rating for the company. Finally, Zacks Research upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Candel Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.57.

Insider Activity at Candel Therapeutics

In other Candel Therapeutics news, insider Francesca Barone sold 23,447 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the transaction, the insider owned 77,362 shares of the company’s stock, valued at $778,261.72. This represents a 23.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.02, for a total transaction of $70,140.00. Following the transaction, the chief technology officer directly owned 83,865 shares of the company’s stock, valued at $840,327.30. This represents a 7.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 14.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC bought a new stake in Candel Therapeutics during the 1st quarter worth about $845,000. Halter Ferguson Financial Inc. grew its holdings in shares of Candel Therapeutics by 20.9% in the 1st quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock valued at $4,430,000 after acquiring an additional 155,996 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Candel Therapeutics in the second quarter valued at about $419,000. Renaissance Technologies LLC bought a new stake in Candel Therapeutics during the first quarter worth about $63,000. Finally, AlphaCentric Advisors LLC bought a new stake in Candel Therapeutics during the first quarter worth about $178,000. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Stock Down 3.7%

The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05. The firm has a 50-day moving average of $9.62 and a 200 day moving average of $7.37. The stock has a market capitalization of $832.42 million, a price-to-earnings ratio of -11.58 and a beta of -0.51.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.